Noted Nephrologist Dr Kirpal Singh Chugh passed away in Chandigarh

M Neelam Kachhap
M Neelam Kachhap
· 2 min read
Dr Chugh receiving D.Sc. (Honoris Cause), Dr NTR University, 2016

Dr Kirpal Singh Chugh, 85, passed away in Chandigarh, today. Dr Chugh was suffering from blood cancer since last two years and was admitted to the Postgraduate Institute of Medical Education and Research (PGIMER) here a few days ago, his family said. He is survived by his wife Harjeet Chugh, 80 and two sons — Sumeet and Sumant, both doctors and settled in the US. IndiaMedToday send deepest condolences to the family and friends of Dr Chugh.

Dr Chugh was born on December 12, 1932 in Patti, Amritsar, India. He did MBBS from the Medical School in Amritsar, in 1955. His first paper in nephrology in 1958, was the first systematic study in the field of kidney diseases in India. He passed MD (Medicine) with kidney diseases in 1961 and became the first qualified nephrologist of India. He set up the first Department of Nephrology in the PGIMER, Chandigarh in 1963. He initiated the dialysis program at the PGI in 1963 and renal transplant program in 1973. He started the first super-specialty course in Nephrology for the award of DM degree at the PGIMER, Chandigarh in 1969 and the first batch of students passed out in 1971, one year before the first Board Certification Exam in Nephrology which was held in 1972. He has been responsible for training more than 75% of the senior nephrology consultants and teachers in the country, several of whom have been heading various nephrology centers or are occupying important positions in India & abroad.

Dr Chugh is popularly known as the “Father of Nephrology” in India a title which has been endorsed by the American College of Physicians, Royal College of Physicians of London and International Society of Nephrology.

He has received numerous national and international awards including Padma Shree , Hony. Fellowship of the Royal College of Physicians, London (FRCP, London), Honorary Fellowship of the American College of Physicians (Honorary FACP), D.Sc. (Honoris causa) Punjabi University (2010), D.Sc. (Honoris causa) GNDU, Amritsar (2013), D.Sc. (Honoris Cause), Dr NTR University, 2016.

A man with astounding productivity, to date he has published 413 papers including 38 chapters, in International and National Journals and Textbooks.

Dr Chugh’s demise is a great loss for the Indian medical community, especially to the super speciality of nephrology.

 

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk